CN109331143B - A herba cistanches Deserticolae composition and its preparation method - Google Patents
A herba cistanches Deserticolae composition and its preparation method Download PDFInfo
- Publication number
- CN109331143B CN109331143B CN201811285049.0A CN201811285049A CN109331143B CN 109331143 B CN109331143 B CN 109331143B CN 201811285049 A CN201811285049 A CN 201811285049A CN 109331143 B CN109331143 B CN 109331143B
- Authority
- CN
- China
- Prior art keywords
- parts
- compound
- group
- weight
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a desert cistanche compound and a preparation method thereof, the desert cistanche compound mainly comprises spirulina, desert cistanche, curcumin, kudzu vine root, ganoderma lucidum powder, lycopene and ginkgo leaf extract, and the traditional Chinese medicine composition has the functions of promoting blood circulation by removing blood stasis, relieving fatigue and preventing senile dementia.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a desert cistanche compound and a preparation method thereof.
Background
Alzheimer's disease, also known as senile dementia, is a progressive degenerative disease of the nervous system with occult disease, characterized clinically by global dementia such as memory impairment, aphasia, disuse, agnosia, impairment of visual spatial skills, dysfunction in execution, and personality and behavioral changes, with patients before 65 years old called presenile dementia and patients after 65 years old becoming senile dementia. With the arrival of aging of the Chinese society, the number of the elderly population is gradually increased, the number of the elderly suffering from senile dementia is also increased year by year, the living capacity of the patients is influenced, and the elderly become burdens on families and society.
Disclosure of Invention
In order to solve the technical problems, the invention provides a cistanche compound and a preparation method thereof, wherein the cistanche compound has the effects of promoting blood circulation, removing blood stasis and relieving fatigue, can be used for preventing senile dementia, has an obvious effect, has no side effect, and can be taken for a long time.
The specific technical scheme of the invention is as follows:
the invention provides a desert cistanche compound which mainly comprises, by weight, 40-50 parts of spirulina, 16-20 parts of desert cistanche, 2-4 parts of turmeric extract, 2-4 parts of kudzu root, 2-4 parts of ganoderma lucidum powder, 2-4 parts of lycopene and 2-4 parts of ginkgo leaf extract.
Wherein, the turmeric extract and the ginkgo leaf extract can be extracted by a method which can be realized in pharmacy, and each 100g of the ginkgo leaf extract contains about 500 mg of total flavonoids and 600mg of total flavonoids; according to the invention, a large number of experimental researches prove that the cistanche compound consisting of spirulina, cistanche, turmeric extract, kudzu root, ganoderma lucidum powder, lycopene and ginkgo leaf extract is applied, the components are compatible with each other, the synergy is realized, and the effects of promoting blood circulation, removing blood stasis, relieving fatigue and preventing senile dementia can be realized.
In a further improvement, the desert cistanche compound also comprises 4-6 parts by weight of dunaliella salina and 4-6 parts by weight of euglena.
According to the invention, the compound is added with the mixture of dunaliella salina and euglena, so that the compound can generate a synergistic effect with the compound, and the effect of promoting blood circulation and removing blood stasis of the compound is further improved.
In a further improvement, the turmeric extract is prepared by the following method:
taking fresh turmeric according to the formula amount, adding 50-60% of ethanol by volume fraction, homogenizing and grinding for 8-10min, wherein the revolution of the homogenizing is 5000-6000r/min, the solid-to-liquid ratio of the fresh turmeric to the ethanol is 1:6-8, the whole homogenizing process is protected from light, the temperature is set to be 15-18 ℃, merging the filtrates, concentrating to 1/6-1/5 of the original volume, and freeze-drying to powder to obtain the turmeric extract.
Wherein, the feed-liquid ratio refers to the ratio of the weight g of a certain substance to the volume mL of liquid.
Further improvement, the specific method for freeze-drying is as follows: placing the concentrated filtrate in cultureSealing the top of the dish with a preservative film, and pricking holes on the preservative film, wherein the hole density is 2-3/cm2Placing the sealed culture dish in a freeze-drying box, adjusting the vacuum degree to-30.0 +/-2 pa, pre-freezing the culture dish at-36 +/-2 ℃, preserving the heat for 1.2-1.4h, raising the temperature for 0.4h at a first-stage heating rate of 20 ℃/h, preserving the heat for 1h, raising the temperature for 0.5h at a second-stage heating rate of 15 ℃/h, preserving the heat for 3h at a third-stage heating rate of 40 ℃/h, raising the temperature for 0.8h, preserving the heat for 5h at a fourth-stage heating rate of 30 ℃/h, raising the temperature for 0.5h, preserving the heat for 4h, and taking out the culture dish to obtain the curcuma longa extract.
The invention specifically limits the preparation method of the turmeric, removes coarse extract and non-medicinal components, and further improves the fatigue relieving effect of the compound.
In order to be convenient to take, the compound and the auxiliary materials are prepared into tablets, wherein the weight part ratio of the compound to the auxiliary materials is 4-10: 1-2; the auxiliary materials comprise 4-6 parts by weight of pea starch, 10-14 parts by weight of debranched waxy starch and 14-16 parts by weight of microcrystalline cellulose, and the moisture absorption of the tablet can be remarkably reduced by adding the compound of the pea starch, the debranched waxy starch and the microcrystalline cellulose into the tablet.
The tablet is further improved, the auxiliary materials also comprise 6-8 parts by weight of sodium carboxymethyl starch, 10-15 parts by weight of low-substituted hydroxypropyl cellulose and 4-8 parts by weight of calcium glutamate chelate.
The invention also provides a preparation method of the compound, which comprises the following steps: drying Cistanchis herba and radix Puerariae, pulverizing in a pulverizer, mixing with Spirulina, Curcuma rhizome extract, Ganoderma powder, lycopene and folium Ginkgo extract, and sieving with 60 mesh sieve to obtain the compound.
The invention also provides the application of the cistanche deserticola compound in preparing the medicines for promoting blood circulation to remove blood stasis, relieving fatigue and treating senile dementia.
The invention has the beneficial effects that: the invention provides a desert cistanche compound which has the functions of promoting blood circulation to remove blood stasis, relieving fatigue and preventing senile dementia.
Detailed Description
Example 1A composite
The compound consists of 40 parts of spirulina, 16 parts of cistanche salsa, 2 parts of turmeric extract, 2 parts of kudzuvine root, 2 parts of ganoderma lucidum powder, 2 parts of lycopene and 2 parts of ginkgo leaf extract.
Example 2A composite
The compound consists of 45 parts of spirulina, 18 parts of cistanche salsa, 3 parts of turmeric extract, 3 parts of kudzuvine root, 3 parts of ganoderma lucidum powder, 3 parts of lycopene and 3 parts of ginkgo leaf extract;
drying Cistanchis herba and radix Puerariae, pulverizing in a pulverizer, mixing with Spirulina, Curcuma rhizome extract, Ganoderma powder, lycopene and folium Ginkgo extract, and sieving with 60 mesh sieve to obtain compound.
Example 3A composite
The compound consists of 50 parts of spirulina, 20 parts of cistanche salsa, 4 parts of turmeric extract, 4 parts of kudzuvine root, 4 parts of ganoderma lucidum powder, 4 parts of lycopene and 4 parts of ginkgo leaf extract;
wherein, the turmeric extract is prepared by the following method:
taking fresh turmeric according to the formula amount, adding 50% ethanol by volume fraction, homogenizing and grinding for 8min, wherein the revolution of the homogenizing is 5000r/min, the solid-liquid ratio of the fresh turmeric to the ethanol is 1:6, the whole homogenizing process is carried out in a dark place, the temperature is set to be 18 ℃, filtrates of each time are combined, the filtrate is concentrated to 1/6 of the original volume, and the turmeric extract is obtained by freeze-drying to powder;
the freeze-drying method comprises the following specific steps: placing the concentrated filtrate in a culture dish, sealing with a preservative film, and pricking holes with a hole density of 2/cm on the preservative film2Placing the sealed culture dish in a freeze-drying box, adjusting the vacuum degree to-28.0 pa, pre-freezing the culture dish at-38 ℃, preserving heat for 1.2h, raising the temperature at 20 ℃/h for the first stage, raising the temperature for 0.4h, preserving heat for 1h, raising the temperature at 15 ℃/h for the second stage, raising the temperature for 0.5h, preserving heat for 3h, raising the temperature at 40 ℃/h for the third stage, raising the temperature for 0.8h, preserving heat for 5h, raising the temperature at 30 ℃/h for the fourth stage, raising the temperature for 0.5hh, keeping the temperature for 4h, and taking out to obtain the curcuma extract.
Example 4A composite
The compound consists of 40 parts of spirulina, 16 parts of cistanche salsa, 2 parts of turmeric extract, 2 parts of kudzuvine root, 2 parts of ganoderma lucidum powder, 2 parts of lycopene and 2 parts of ginkgo leaf extract;
wherein, the turmeric extract is prepared by the following method:
taking fresh turmeric according to the formula amount, adding 60% ethanol by volume, homogenizing and grinding for 10min, wherein the revolution of the homogenizing is 6000r/min, the solid-to-liquid ratio of the fresh turmeric to the ethanol is 1:8, the whole homogenizing process is carried out in a dark place, the temperature is set to be 15 ℃, filtrates of each time are combined, the filtrate is concentrated to 1/5 of the original volume, and the turmeric extract is obtained after freeze-drying to powder;
the freeze-drying method comprises the following specific steps: placing the concentrated filtrate in a culture dish, sealing with a preservative film, and pricking holes with a hole density of 3/cm on the preservative film2Placing the sealed culture dish in a freeze-drying box, adjusting the vacuum degree to-32 pa, pre-freezing at-34 ℃, preserving heat for 1.4h, raising the temperature at 20 ℃/h in the first stage for 0.4h, preserving heat for 1h, raising the temperature at 15 ℃/h in the second stage for 0.5h, preserving heat for 3h, raising the temperature at 40 ℃/h in the third stage for 0.8h, preserving heat for 5h, raising the temperature at 30 ℃/h in the fourth stage for 0.5h, preserving heat for 4h, and taking out to obtain the curcuma longa extract.
Example 5A composite
The compound consists of 40 parts of spirulina, 16 parts of cistanche salsa, 2 parts of turmeric extract, 2 parts of kudzuvine root, 2 parts of ganoderma lucidum powder, 2 parts of lycopene and 2 parts of ginkgo leaf extract;
the compound also comprises 4 parts by weight of dunaliella salina and 4 parts by weight of euglena.
Example 6A composite
The compound consists of 45 parts of spirulina, 18 parts of cistanche salsa, 3 parts of turmeric extract, 3 parts of kudzuvine root, 3 parts of ganoderma lucidum powder, 3 parts of lycopene and 3 parts of ginkgo leaf extract;
the compound also comprises 5 parts by weight of dunaliella salina and 5 parts by weight of euglena.
Example 7A composite
The compound consists of 50 parts of spirulina, 20 parts of cistanche salsa, 4 parts of turmeric extract, 4 parts of kudzuvine root, 4 parts of ganoderma lucidum powder, 4 parts of lycopene and 4 parts of ginkgo leaf extract;
the compound also comprises 6 parts by weight of dunaliella salina and 6 parts by weight of euglena.
Example 8A tablet
The tablet comprises the following components in parts by weight:
example 9A tablet
The tablet comprises the following components in parts by weight:
the tablet is prepared by the following method:
(1) preparing a composite;
(2) taking pea starch, debranched waxy starch and microcrystalline cellulose according to the formula ratio, adding 3 times of water, fully and uniformly mixing, adding the compound prepared in the step (1), and uniformly mixing again to prepare a soft material;
(3) and (3) granulating the soft material prepared in the step (2), grading, and tabletting to obtain the tablet.
EXAMPLE 10A tablet
The tablet comprises the following components in parts by weight:
EXAMPLE 11A tablet
The tablet comprises the following components in parts by weight:
comparative example 1A Compound
The compound consists of 45 parts of chlorella, 18 parts of cistanche salsa, 3 parts of turmeric extract, 3 parts of kudzuvine root, 3 parts of ganoderma lucidum powder, 3 parts of lycopene and 3 parts of ginkgo leaf extract;
the composite was prepared by the method of example 2.
Comparative example 2A Compound
The compound mainly comprises 45 parts of spirulina, 18 parts of cistanche, 3 parts of quercetin, 3 parts of radix bupleuri, 3 parts of coriolus versicolor powder, 3 parts of vitamin E and 3 parts of ginkgo leaf extract by weight;
the composite was prepared by the method of example 2.
Comparative example 3A Compound
The compound consists of 50 parts of spirulina and 20 parts of cistanche salsa by weight;
the composite was prepared by the method of example 2.
Comparative example 4A Compound
The compound consists of 50 parts of spirulina, 20 parts of cistanche salsa, 4 parts of turmeric extract, 4 parts of kudzuvine root, 4 parts of ganoderma lucidum powder, 4 parts of lycopene and 4 parts of ginkgo leaf extract;
wherein, the turmeric extract is prepared by the following method:
taking fresh turmeric according to the formula amount, adding 50% ethanol by volume fraction, homogenizing and grinding for 8min, wherein the revolution of the homogenizing is 5000r/min, the solid-liquid ratio of the fresh turmeric to the ethanol is 1:6, the whole homogenizing process is carried out in a dark place, the temperature is set to be 18 ℃, filtrates of each time are combined, the filtrate is concentrated to 1/6 of the original volume, and the turmeric extract is obtained by freeze-drying to powder;
the freeze-drying method comprises the following specific steps: standing the concentrated filtrateIn the culture dish, the top is sealed by a preservative film, holes are punctured on the preservative film, and the density of the holes is 1/cm2Placing the sealed culture dish in a freeze-drying box, adjusting the vacuum degree to-28.0 pa, pre-freezing at-38 deg.C, and keeping the temperature for 16.4h, and taking out to obtain Curcuma rhizome extract;
the composite was prepared by the method of example 2.
Comparative example 5A Compound
The compound consists of 45 parts of spirulina, 18 parts of cistanche salsa, 3 parts of turmeric extract, 3 parts of kudzuvine root, 3 parts of ganoderma lucidum powder, 3 parts of lycopene and 3 parts of ginkgo leaf extract;
the compound also comprises 5 parts by weight of dunaliella salina and 5 parts by weight of euglena.
Comparative example 6A Compound
The compound consists of 45 parts of spirulina, 18 parts of cistanche salsa, 3 parts of turmeric extract, 3 parts of kudzuvine root, 3 parts of ganoderma lucidum powder, 3 parts of lycopene and 3 parts of ginkgo leaf extract;
the compound also comprises 5 parts by weight of dunaliella salina and 5 parts by weight of euglena.
Comparative example 7A Compound
The compound consists of 45 parts of spirulina, 18 parts of cistanche salsa, 3 parts of turmeric extract, 3 parts of kudzuvine root, 3 parts of ganoderma lucidum powder, 3 parts of lycopene and 3 parts of ginkgo leaf extract;
the compound also comprises 5 parts by weight of dunaliella salina and 5 parts by weight of euglena. Comparative example 8A tablet
The tablet comprises the following components in parts by weight:
the tablet was prepared using the method of example 11.
Comparative example 9A tablet
The tablet comprises the following components in parts by weight:
composite 10 of example 2
Pea starch 0.56
Microcrystalline cellulose 0.44;
the tablet was prepared using the method of example 11.
Comparative example 10A tablet
The tablet comprises the following components in parts by weight:
comparative example 11A tablet
The tablet comprises the following components in parts by weight:
experimental example 1 therapeutic effect on Qi-stagnation and blood stasis model rats
Taking 190 healthy SD rats, female, with the weight of 203 +/-11.3 g, randomly dividing into blank groups, model groups, test 1-5 groups, control 1-5 groups, spirulina groups, cistanche deserticola groups, turmeric extract groups, kudzu root groups, lucid ganoderma powder groups, lycopene groups and positive drug groups, wherein each group comprises 10 rats, the rest groups except the blank groups are filled with 20ml/kg of rheum officinale decoction with the concentration of 200%, the rats are placed in a water tank with the water depth of about 40cm and the water temperature of 42 +/-1 ℃ for swimming after one hour until the rats naturally sink and can not float out, the rats are filled with the rheum officinale decoction once a day for 14 days continuously, the filling and the administration are started after 11 days after the model building, the test 1-5 groups use the compounds of examples 1-2 and 5-7, the control 1-5 groups use the compounds of the controls 1-2 and 5-7, the blank groups and the model groups use equal amounts of distilled water, the spirulina groups, the model groups, the spirulina groups and the spirulina groups, the cistanche deserticola, Respectively adding Spirulina powder, Cistanchis herba powder, Curcuma rhizome extract, radix Puerariae powder, Ganoderma powder, lycopene and folium Ginkgo extract into Cistanchis herba group, Curcuma rhizome extract group, radix Puerariae group, Ganoderma powder, lycopene and folium Ginkgo groupThe material and the positive drug group are prepared from compound salvia miltiorrhiza tablets, the dosage is 200mg/kg and d, the compound salvia miltiorrhiza tablets are continuously administrated for 10 days, 1h after the last administration, 30mg/kg of anesthesia is intraperitoneally injected by using pentobarbital sodium, 10ml of blood is taken from heart, the blood is anticoagulated by using heparin sodium 31.25u/ml, and then the specific viscosity of the whole blood is measured by using a viscosity meter (the cutting speed is respectively 9.6S)-1And 192S-1The whole blood was mixed and injected into a hematocrit tube at a constant temperature of 25 ℃ and centrifuged at 3000rmp for 30 minutes, and the hematocrit was observed and recorded, and the results are shown in table 1 (see the method of this test example in patent No. CN 101933991B).
TABLE 1 Effect of each group of drugs on the blood rheology of rats with qi stagnation and blood stasis
As can be seen from table 1, the indexes of the rats in the groups 1 to 5 after the drug administration are all lower than those of the control groups 1 to 5, the spirulina group, the cistanche group, the turmeric extract group, the pueraria root group, the ganoderma lucidum powder group, the lycopene group and the positive drug group, which shows that the compound provided by the invention can play a better role in promoting the circulation of qi and blood, and when a certain component in the compound provided by the invention is singly used or replaced by other components, the effect of promoting the circulation of blood and removing stasis can be reduced.
Test example 2 anti-fatigue action
Taking 150 Kunming mice with each half of male and female, the weight of 18-22g, provided by medical experimental animals of Lanzhou university, feeding the mice with granular common feed, drinking tap water, feeding for 3d, and then dividing the mice into a blank group, a test group 6-9 group, a control group 6-9 group, a spirulina group, a cistanche deserticola group, a turmeric extract group, a radix puerariae group, a ganoderma lucidum powder group, a lycopene group and a ginkgo leaf extract group, wherein each group comprises 10 mice, performing gastric lavage according to the body weight, continuously administering for 30 days, the blank group is administered with physiological saline with the same amount, the test group 6-9 group is administered with the compound of example 1-4, the control group 6-9 group is administered with the compound of example 1-4, the spirulina group, the cistanche deserticola group, the turmeric extract group, the radix puerariae group, the ganoderma lucidum powder group, the lycopene group and the ginkgo leaf group are respectively administered with spirulina powder, cistanche deserticola powder, a turmeric extract, Kudzu root powder, Ganoderma lucidum powder, lycopene and Ginkgo biloba leaf extract were administered at 300 mg/kg. d, and 30min after the last administration, the mice were placed in a swimming box with a 5% weight lead skin at the root of the rat tail and swimed at a water depth of not less than 30cm and a water temperature of 25 ℃. + -. 1.0 ℃, and the time from the start of swimming to death of the mice, i.e., the time of swimming under load of the mice, was recorded, and the results are shown in Table 2 (see the method in patent No. 201711200993.7 for the method of this test example).
TABLE 2 swimming time under load for each group of mice
As can be seen from table 2, the compound of the present invention in test examples 1 to 4 was significantly longer in the duration of heavy swimming than the other groups after administration, and thus it was confirmed that the compound of the present invention can effectively relieve physical fatigue, and that the compound of the present invention has a fatigue relieving effect that is reduced when a certain component of the compound of the present invention is used alone or when a certain component of the compound of the present invention is replaced or deleted, and the compound of examples 3 to 4 has a fatigue relieving effect that is significantly higher than the compound of examples 1 to 2, and thus it was confirmed that the method for preparing the turmeric extract provided by the present invention can significantly improve the fatigue relieving effect, and that the method for preparing the turmeric extract can also reduce the fatigue relieving effect of the compound when the method for preparing the turmeric extract is changed.
Test example 3 preventive Effect against Alzheimer's disease
Taking 130 female KM mice, dividing into blank group, model group, experiment 10-11 group, control group 10-11 group, spirulina group, desert cistanche group, turmeric extract group, kudzu root group, glossy ganoderma powder group, lycopene group and ginkgo leaf extract group, feeding the animals into gastric lavage, feeding the compound of example 1-2 into experiment 10-11 group, feeding the compound of comparative example 1-2 into control 10-11 group, respectively feeding spirulina powder, desert cistanche group, turmeric extract group, kudzu root group, glossy ganoderma powder group, lycopene group and ginkgo leaf group into spirulina powder, desert cistanche powder, turmeric extract, kudzu root powder, glossy ganoderma powder, lycopene and ginkgo leaf extract, respectively feeding the water with the same dose into blank group and model group, feeding the dose of 200 mg/kg. d for 10 days, feeding the scopolamine into the animals in each group 1h after the last time, except for the blank group, feeding the scopolamine 3mg/kg, after 10min, the test was repeated for 3min, 5min, 24h, and the mice were placed on the platform and the number of errors (from the platform) was recorded for 5min, as shown in table 3 (see patent CN103055014B for the method of this test example).
TABLE 3 Effect of each group of complexes on scopolamine-induced memory acquisition disorders in mice
As can be seen from table 3, the composite provided in the invention experiments 10-11 can significantly reduce the number of errors in mice, and the effect is significantly higher than that of the control group 10-11, the spirulina group, the cistanche group, the turmeric extract group, the pueraria root group, the ganoderma lucidum powder group, the lycopene group and the ginkgo leaf extract group, which proves that the composite provided in the invention can effectively prevent senile dementia, and when a certain component in the composite provided in the invention is used alone or certain components in the invention are replaced or deleted, the effect of preventing senile dementia can be reduced.
Test example 4 hygroscopicity measurement test of tablet
The tablets of examples 8 to 9 and comparative examples 8 to 9 were each taken, placed in a desiccator and cooled naturally, the dried sample was placed in a measuring cup with a lid after drying, the weight of the measuring cup and the sample was recorded, the measuring cup with the dried sample was placed in a moisture-retaining device, the lid was opened, the start date, time and weather conditions were recorded, and a relative humidity meter was placed in the moisture-retaining device, and the relative humidity value and observation time were recorded at a constant time corresponding to room temperature. The sample cups in the humidor were closed after 24h, and the weighing records were taken out one by one, and the test results are shown in table 4.
TABLE 4 hygroscopicity of tablets of the respective groups
As can be seen from Table 4, the tablets of examples 8 to 9 had a lower hygroscopicity than the tablets of comparative examples 8 to 9, and it was found that the addition of a mixture of pea starch, debranched waxy starch and microcrystalline cellulose to the tablets had the effect of reducing the hygroscopicity of the tablets, and that the hygroscopicity of the tablets was increased when any one of the components was deleted or replaced.
Test example 5 disintegration time test of tablet
The tablets of examples 10 to 11 and comparative examples 10 to 11 were taken and their disintegration time was measured, and 6 replicates of each group were sampled and the results were averaged, and the test results are shown in Table 5.
TABLE 5 disintegration time test results for each set of tablets
As can be seen from Table 5, the tablets of examples 10 to 11 had significantly lower disintegration time than the tablets of comparative examples 10 to 11, and it can be understood that the addition of a mixture of sodium carboxymethyl starch, low-substituted hydroxypropylcellulose and chelated calcium glutamate to the tablets served to shorten the disintegration time, which resulted in an increase in the disintegration time of the tablets when any one of the ingredients was deleted or replaced.
Claims (4)
1. A cistanche compound is characterized in that the compound consists of 40-50 parts of spirulina, 16-20 parts of cistanche, 2-4 parts of turmeric extract, 2-4 parts of kudzu root, 2-4 parts of ganoderma lucidum powder, 2-4 parts of lycopene, 2-4 parts of ginkgo leaf extract, 4-6 parts of dunaliella salina and 4-6 parts of euglena by weight;
the turmeric extract is prepared by the following method:
taking fresh turmeric according to the formula amount, adding 50-60% of ethanol by volume fraction, homogenizing and grinding for 8-10min, wherein the revolution of the homogenizing is 5000-;
the specific method for freeze-drying comprises the following steps: placing the concentrated filtrate in a culture dish, sealing with a preservative film, and pricking holes with a hole density of 2-3/cm on the preservative film2Placing the sealed culture dish in a freeze-drying box, adjusting the vacuum degree to-30.0 +/-2 pa, pre-freezing the culture dish at-36 +/-2 ℃, preserving the heat for 1.2-1.4h, raising the temperature for 0.4h at a first-stage heating rate of 20 ℃/h, preserving the heat for 1h, raising the temperature for 0.5h at a second-stage heating rate of 15 ℃/h, preserving the heat for 3h at a third-stage heating rate of 40 ℃/h, raising the temperature for 0.8h, preserving the heat for 5h at a fourth-stage heating rate of 30 ℃/h, raising the temperature for 0.5h, preserving the heat for 4h, and taking out the culture dish to obtain the curcuma longa extract.
2. A tablet, comprising the compound of claim 1 and an adjuvant, wherein the weight part ratio of the compound to the adjuvant is 4-10: 1-2; the auxiliary materials comprise 4-6 parts of pea starch, 10-14 parts of debranched waxy starch and 14-16 parts of microcrystalline cellulose.
3. The tablet of claim 2, wherein the excipients further comprise 6 to 8 parts by weight of sodium carboxymethyl starch, 10 to 15 parts by weight of low-substituted hydroxypropyl cellulose, and 4 to 8 parts by weight of calcium glutamate chelate.
4. The use of the cistanche salsa compound as set forth in claim 1 for the preparation of a medicament for activating blood circulation to dissipate blood stasis, alleviating fatigue and preventing senile dementia.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811285049.0A CN109331143B (en) | 2018-10-30 | 2018-10-30 | A herba cistanches Deserticolae composition and its preparation method |
| CN202210481134.4A CN114887018A (en) | 2018-10-30 | 2018-10-30 | A herba cistanches composite and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811285049.0A CN109331143B (en) | 2018-10-30 | 2018-10-30 | A herba cistanches Deserticolae composition and its preparation method |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210481134.4A Division CN114887018A (en) | 2018-10-30 | 2018-10-30 | A herba cistanches composite and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109331143A CN109331143A (en) | 2019-02-15 |
| CN109331143B true CN109331143B (en) | 2022-07-08 |
Family
ID=65312896
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210481134.4A Pending CN114887018A (en) | 2018-10-30 | 2018-10-30 | A herba cistanches composite and its preparation method |
| CN201811285049.0A Active CN109331143B (en) | 2018-10-30 | 2018-10-30 | A herba cistanches Deserticolae composition and its preparation method |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210481134.4A Pending CN114887018A (en) | 2018-10-30 | 2018-10-30 | A herba cistanches composite and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN114887018A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104095897A (en) * | 2014-06-24 | 2014-10-15 | 伏思思 | Maca dunaliella salina compound preparation |
| CN104524182A (en) * | 2014-12-08 | 2015-04-22 | 上海焦点生物技术有限公司 | Traditional Chinese medicine composition for improving memory |
| CN105919136A (en) * | 2016-05-21 | 2016-09-07 | 陕西泓逺金道生物科技有限公司 | Nutrition supplement composition with fatigue resisting and immunity improving effects and preparation and preparation method thereof |
| CN106139019A (en) * | 2016-08-10 | 2016-11-23 | 北京润康普瑞生物技术有限公司 | A kind of Chinese medicine composition improving dementia and its preparation method and application |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101168025B (en) * | 2007-10-25 | 2010-06-23 | 北京师范大学 | Medicine composition for preventing and treating senile dementia |
| CN101731622A (en) * | 2010-02-10 | 2010-06-16 | 宁波御坊堂生物科技有限公司 | Lucid ganoderma spirulina tablet and preparation process thereof |
| CN102813753B (en) * | 2012-05-22 | 2014-02-26 | 孟令刚 | Composition containing Cistanche deserticola or Herba Cynomorii and combination of chrysanthemum, taurine, lycopene, xanthophyll and beta-carotene |
-
2018
- 2018-10-30 CN CN202210481134.4A patent/CN114887018A/en active Pending
- 2018-10-30 CN CN201811285049.0A patent/CN109331143B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104095897A (en) * | 2014-06-24 | 2014-10-15 | 伏思思 | Maca dunaliella salina compound preparation |
| CN104524182A (en) * | 2014-12-08 | 2015-04-22 | 上海焦点生物技术有限公司 | Traditional Chinese medicine composition for improving memory |
| CN105919136A (en) * | 2016-05-21 | 2016-09-07 | 陕西泓逺金道生物科技有限公司 | Nutrition supplement composition with fatigue resisting and immunity improving effects and preparation and preparation method thereof |
| CN106139019A (en) * | 2016-08-10 | 2016-11-23 | 北京润康普瑞生物技术有限公司 | A kind of Chinese medicine composition improving dementia and its preparation method and application |
Non-Patent Citations (2)
| Title |
|---|
| "不同比例螺旋藻多糖与银杏叶提取物对小鼠抗疲劳作用的研究";于蕾妍等;《中国兽药杂志》;20180731;第52卷(第7期);第72-77页 * |
| 脑立轻对拟血管性疾呆大鼠治疗的实验研究;王正君等;《中国中医急症》;20080415;第17卷(第04期);第516-517页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114887018A (en) | 2022-08-12 |
| CN109331143A (en) | 2019-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2555235A1 (en) | Plant-based medicament for the treatment of hepatitis c | |
| CN103099833A (en) | Soft capsule helpful for relieving sports fatigue and delaying aging and preparation method thereof | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN103690582B (en) | A kind of compositions and application thereof containing dendrobium polysaccharide and atractylis concrete | |
| CN109331143B (en) | A herba cistanches Deserticolae composition and its preparation method | |
| CN102526444A (en) | Traditional Chinese medicine composition for invigorating kidney and strengthening yang and preparation method thereof | |
| KR20140143952A (en) | Arthritis Remedy Composition and manufacture method having immunity and the circulation of the blood improvement fuction | |
| CN101745017B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
| CN101745011B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
| CN101745012B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
| CN112057536B (en) | Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof | |
| CN108126062B (en) | Oral traditional Chinese medicine composition for treating depression, preparation and preparation method thereof | |
| CN112057535B (en) | Preparation method of traditional Chinese medicine composition for preventing or/and treating dyslipidemia | |
| CN101745005B (en) | Extraction method of ophiopogon root, ginseng and shiandra and preparation thereof | |
| CN101745000B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN101744989B (en) | Method for extracting schisandra chinensis, ginseng and dwarf lilyturf root and preparation thereof | |
| CN101745015B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
| CN101745001B (en) | Extraction method of ophiopogon root, ginseng and shiandra and preparation thereof | |
| CN101745008A (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN101745016A (en) | Extraction method of 'ginseng/radix ophiopogonis and schisandra chinensis' and preparation thereof | |
| CN105616706A (en) | Shenling (panax quinquefolius and ganoderma lucidum) granules for strengthening body resistance and preparation method thereof | |
| CN112336796A (en) | Pharmaceutical composition with effects of relieving anxiety and improving depression and application thereof | |
| CN101745002B (en) | Extraction method of ophiopogon root, ginseng and shiandra and preparation thereof | |
| CN101744998B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN101744995B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |